Click me
Transcribed

2014 Clinical Development Year in Review

ISR's Clinical Development ISRreports.com | info@ISRreports.com | @ISRreports vear in The Pharma & Biotech stock index grew by more than 32.5% in 2014, and the increasing number of public CROS saw their stock prices rise as well. In 2014, the clinical development industry saw an increased shift toward Risk-Based Monitoring methodologies and an increased reliance on eClinical technologies. For more information on these trends and ISR's CRO market size projections through 2018, visit www.ISRreports.com. revew eClinical eClinical technology continued to play a growing role in clinical development in 2014. ISR's research found that "integration" is gaining the most importance among eClinical system users. EDC IRT EPRO growth Pharma & Biotech Stock Index ISR's respondents said they integrate CTMS applications with: +32.5% EDC systems 44% of the time IRT systems 17% of the time EPRO systems 15% of the time CRO Stock Price (Q, PRXL, CVD, ICON, CRL) +16.2% going public 2014 saw even more CROS going public, a trend that PAREXEL's SVP and CFO, Ingo Bank, said he expects to continue in the coming years. 2014 IPO 3Q 2014 Already Public Covance 2014 3Q 2013 ICON INC Pharma R&D RESEARCH -4.5% PRA PAREXEL Quintiles trends ncreasing use of muliple countries Technology becoming Increasingly crltical Growing use of RBM Expansion of preferred provider lists m&a Merger and Acquisition activity in the Pharmaceutical and Life Science Industry continued to grow in 2014. Total deal value (Q1-Q3): China becoming more common for subject recruitment More complex trials eClinical data integration on the rise IND applications $121B Q3 Q2 $106B ram Number of Investigational New Drug applications, by quarter 2014 saw an increase in the number of clinical trials using Risk-Based Monitoring. For details on the growth and implementation of RBM, see ISR's "The Evolution of Risk-Based Monitoring" infographic. Q1 $18B 176 $79B $61B $11B 65% of ISR ISR respondents $21B report that 40% of their Phase respondents 107 consider their 92 93 $15B 65% 40% iMil stdies volume of risk-based 78 72 66 64 $37B $77B monitoring in Phase I/II studies to be increasing. include risk-based monitoring. $45B $21B Oct.- Dec. 2012 Jan. - March 2013 April - June 2013 July - Sept. 2013 Oct. - Dec. 2013 Jan. - March 2014 April - June 2014 July Sept. 2014 ISR Research Thomson Reuters ISR's "CTMS Market Dynam- ISR's "The Evolution of ics and Service Provider 2012 2013 2014 fda.gov google.com/finance Benchmarking" Risk-Based Monitoring PwC SOURCES: percent growth

2014 Clinical Development Year in Review

shared by ISRreports on Jan 28
125 views
0 shares
0 comments
The Pharma & Biotech stock index grew by more than 32.5% in 2014, and the increasing number of public CROs saw their stock prices rise as well. In 2014, the clinical development industry saw an increa...

Category

Other
Did you work on this visual? Claim credit!

Get a Quote

Embed Code

For hosted site:

Click the code to copy

For wordpress.com:

Click the code to copy
Customize size